Tecentriq® (atezolizumab) – New indication

- On March 18, 2019, Genentech announced the FDA approval of Tecentriq (atezolizumab), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

- Tecentriq is also approved for the treatment of patients with urothelial carcinoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer.

- According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2019. SCLC accounts for approximately 13% of all cases. Approximately 70% of people with SCLC are diagnosed with ES-SCLC.

- The approval of Tecentriq's new indication was based on IMpower133, a double-blind study in 403 patients with ES-SCLC. Patients were randomized to receive Tecentriq + carboplatin + etoposide or placebo + carboplatin + etoposide. Major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS).

    - Median OS was 12.3 months for the Tecentriq arm vs. 10.3 months for the placebo arm (Hazard Ratio [HR] 0.70; 95% CI: 0.54, 0.91; p = 0.0069).
    - Medan PFS was 5.2 months for the Tecentriq arm vs. 4.3 months for the placebo arm (HR 0.77; 95% CI: 0.62, 0.96; p = 0.017).
    - The objective response rate was 60% (95% CI: 53, 67) for the Tecentriq arm vs. 64% (95% CI: 57, 71) for the placebo arm.
    - The median duration of response was 4.2 months (95% CI: 4.1, 4.5) for the Tecentriq arm vs. 3.9 months (95% CI: 3.1, 4.2) for the placebo arm.

- The most common adverse reactions (≥ 20%) with Tecentriq in combination with other antineoplastic drugs in patients with NSCLC and SCLC were fatigue/asthenia, nausea, alopecia, constipation, diarrhea, and decreased appetite.

- The recommended dosage of Tecentriq for SCLC is 1200 mg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.

    - When administering Tecentriq in combination with chemotherapy, administer Tecentriq prior to chemotherapy when given on the same day.
    - Refer to the drug labels for the chemotherapy agents administered in combination with Tecentriq for additional recommended dosing information

- Refer to the Tecentriq drug label for dosing recommendations for its other indications.